GDF-8(Myostatin)For Bodybuilding CAS:271597-12-7

    Introduction to GDF-8 (Myostatin)

    GDF-8, commonly known as myostatin, is a protein encoded by the MSTN gene and a member of the transforming growth factor-beta (TGF-β) superfamily. Discovered in 1997 by geneticists Se-Jin Lee and Alexandra McPherron, myostatin acts as a negative regulator of skeletal muscle growth. Its primary role is to limit muscle hyperplasia (increase in muscle cell number) and hypertrophy (increase in muscle cell size) by inhibiting the proliferation and differentiation of myoblasts (muscle progenitor cells).

    Myostatin's function became widely recognized after studies on genetically modified mice with a non-functional MSTN gene. These "mighty mice" exhibited double the muscle mass of normal mice due to unrestricted muscle growth. Similar phenotypes were later observed in cattle (e.g., Belgian Blue bulls) and humans with myostatin mutations, confirming its conserved role across species.

    Understanding myostatin's biological characteristics is critical for leveraging its manipulation in bodybuilding:

    ●Mechanism of Action:
    Myostatin binds to activin type II receptors (ActRIIB) on muscle cells, activating SMAD signaling pathways. This suppresses mTOR (mechanistic target of rapamycin), a key regulator of protein synthesis, and upregulates ubiquitin-proteasome pathways, leading to muscle atrophy.

    ●Tissue Specificity:
    Predominantly expressed in skeletal muscle, with minor expression in adipose tissue and the heart.

    ●Feedback Regulation:
    Muscle-derived myostatin creates a negative feedback loop. As muscle mass increases, myostatin levels rise to prevent excessive growth.

    ●Genetic Variability:
    Natural mutations (e.g., MSTN loss-of-function) result in hypermuscularity, offering insights into potential therapeutic targets.

    Myostatin inhibition has emerged as a revolutionary strategy for muscle enhancement. Current approaches include:

    A. Pharmacological Inhibitors

    ●Monoclonal Antibodies (e.g., Stamulumab, Domagrozumab): Bind to myostatin, preventing receptor interaction.

    ●Soluble Receptors (e.g., ACE-031): ActRIIB decoys that sequester circulating myostatin.

    ●Small-Molecule Inhibitors: Oral compounds blocking SMAD signaling (e.g., LY2495655).

    B. Gene Therapy

    CRISPR/Cas9 or viral vectors to disrupt the MSTN gene, mimicking natural mutations.

    C. Natural Supplements

    ●Epicatechin: Found in dark chocolate, shown to reduce myostatin levels in preclinical studies.

    ●Follistatin: A glycoprotein that binds and neutralizes myostatin, available as an injectable peptide.

    1.Enhanced Muscle Hypertrophy: Unrestricted mTOR activation promotes protein synthesis.

    2.Fat Loss: Myostatin inhibition correlates with reduced adipogenesis (fat cell formation).

    3.Improved Recovery: Lower inflammation and oxidative stress via downregulated NF-κB pathways.

    4.Muscle Retention During Cutting: Prevents catabolism during caloric deficits.

    5.Synergy with Anabolics: Complements steroids/SARMs by targeting a separate regulatory pathway.

    Note: Most inhibitors remain experimental; human protocols are extrapolated from preclinical data.

    A. Monoclonal Antibodies

    ●Stamulumab: 1–3 mg/kg subcutaneously weekly.

    ●Domagrozumab: 10–20 mg/kg IV monthly.

    B. Follistatin Peptides

    ●Follistatin-344: 100–200 mcg/day subcutaneously, split into two doses.

    C. Epicatechin

    ●Natural Supplementation: 50–100 mg/day orally, derived from cocoa extract.

    Caution: Self-administration risks include immunogenicity (antibody resistance) and unregulated dosing.

    Cycles depend on the compound's half-life and desired outcomes:

    ●Short-Acting Agents (e.g., Follistatin):

    ○8-Week Cycle: 5 days on, 2 days off to prevent receptor desensitization.

    ○Stacking: Combine with IGF-1 for synergistic hypertrophy.

    ●Long-Acting Antibodies (e.g., Domagrozumab):

    ○12-Week Cycle: Single monthly injection, followed by a 6-week washout.

    Post-Cycle Therapy (PCT): Unlike steroids, myostatin inhibitors don't suppress the HPT axis. However, taper doses to avoid rebound myostatin spikes.

    ●Monoclonal Antibodies: 14–21 days (e.g., Domagrozumab).

    ●Follistatin: 4–6 hours, necessitating frequent dosing.

    ●Epicatechin: 2–3 hours, requiring sustained-release formulations.

    ●Musculoskeletal Risks: Rapid hypertrophy may strain tendons/joints.

    ●Cardiac Impact: Myostatin is cardioprotective; long-term inhibition may predispose to fibrosis.

    ●Cancer Risk: Uncontrolled cell proliferation due to mTOR activation.

    ●Dual Targeting: Combining myostatin inhibitors with activin inhibitors (e.g., ACVR2B) for amplified effects.

    ●Nutrigenomic Approaches: Diets rich in omega-3s and leucine to naturally suppress myostatin.

    ●Personalized Medicine: Genetic testing for MSTN polymorphisms to tailor dosing.

    ●WADA Status: Myostatin inhibitors are banned in competitive sports (WADA Prohibited List S4.5).

    ●Regulatory Hurdles: No FDA-approved myostatin-based therapies for muscle enhancement..

Trade Name	latent GDF-8, Myostatin, GDF8, MSTN, Growth, differentiation factor 8
CAS	271597-12-7
Molar mass	25.6 kilodaltons (kDa)
MF	375 amino acids
Purity	Above 98%
Apprarance	1mg/vial,Lyophilized powder

 

 

Any needs, please contact us

Email: Jasonraws106@gmail.com

WhatsApp: +86-15572565525
Telegram: +86-19128233885

   

                                

 

   Myostatin inhibition represents a paradigm shift in bodybuilding, offering unprecedented muscle growth with minimal androgenic side effects. However, ethical concerns, legal restrictions, and unresolved safety issues necessitate caution. As research advances, CRISPR-based therapies and precision dosing may unlock safer, more effective protocols.

Hot Tags: gdf-8(myostatin)for bodybuilding cas:271597-12-7, China gdf-8(myostatin)for bodybuilding cas:271597-12-7 manufacturers, suppliers, factory